You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 14, 2024

CLINICAL TRIALS PROFILE FOR FUTIBATINIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for FUTIBATINIB

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02052778 ↗ A Study of TAS-120 in Patients With Advanced Solid Tumors Completed Taiho Oncology, Inc. Phase 1/Phase 2 2014-07-01 This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts: 1. Dose escalation portion to determine the MTD and/ or RP2D of futibatinib. 2. Phase 1 expansion portion to further evaluate the safety and efficacy of futibatinib in patients with tumors harboring FGF/FGFR aberrations, including patients with cholangiocarcinoma (CCA), primary CNS tumors, urothelial carcinoma, breast cancer, gastric cancer and 3. Phase 2 study portion to confirm ORR of futibatinib in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).
NCT04024436 ↗ A Study of TAS-120 in Patients With Metastatic Breast Cancer Recruiting Taiho Oncology, Inc. Phase 2 2019-08-30 The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.
NCT04093362 ↗ Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Recruiting Taiho Oncology, Inc. Phase 3 2020-03-01 This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced, metastatic, or recurrent unresectable iCCA harboring FGFR2 gene rearrangements
NCT04189445 ↗ Futibatinib in Patients With Specific FGFR Aberrations Recruiting Taiho Oncology, Inc. Phase 2 2020-08-31 The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.
NCT04601857 ↗ Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Recruiting Merck Sharp & Dohme Corp. Phase 2 2021-01-21 The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.
NCT04601857 ↗ Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Recruiting Taiho Oncology, Inc. Phase 2 2021-01-21 The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.
NCT04828486 ↗ Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Recruiting National Cancer Institute (NCI) Phase 2 2021-05-07 This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body (advanced or metastatic). Futibatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving futibatinib and pembrolizumab may help treat patients with FGF19 positive liver cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for FUTIBATINIB

Condition Name

Condition Name for FUTIBATINIB
Intervention Trials
Advanced Cholangiocarcinoma 2
FGFR 1 High Amplification 1
Myeloid or Lymphoid Neoplasms (MLN) 1
Advanced or Metastatic Solid Tumor 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for FUTIBATINIB
Intervention Trials
Cholangiocarcinoma 3
Neoplasms 2
Carcinoma 2
Biliary Tract Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for FUTIBATINIB

Trials by Country

Trials by Country for FUTIBATINIB
Location Trials
United States 47
France 12
Japan 7
United Kingdom 5
Italy 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for FUTIBATINIB
Location Trials
Texas 5
Massachusetts 4
California 4
Arizona 4
Minnesota 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for FUTIBATINIB

Clinical Trial Phase

Clinical Trial Phase for FUTIBATINIB
Clinical Trial Phase Trials
Phase 3 2
Phase 2 6
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for FUTIBATINIB
Clinical Trial Phase Trials
Recruiting 6
Not yet recruiting 3
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for FUTIBATINIB

Sponsor Name

Sponsor Name for FUTIBATINIB
Sponsor Trials
Taiho Oncology, Inc. 8
Mayo Clinic 1
Zymeworks Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for FUTIBATINIB
Sponsor Trials
Industry 13
Other 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.